Literature DB >> 11178960

A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPARgamma.

W A Wilmer1, C Dixon, L Lu, T Hilbelink, B H Rovin.   

Abstract

The mitogen-activated protein (MAP) kinases mediate the response of renal glomerular mesangial cells to a variety of physiologic and pathologic stimuli. This investigation examines the effect of the cyclopentenone prostaglandin 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2) on MAP kinases in human mesangial cells. We show that 15d-PGJ2 dose-dependently increases the extracellular signal-regulated kinase (ERK) activity of human mesangial cells, but has no effect on Jun-NH2-terminal kinase or p38 MAP kinase. Despite the fact that 15d-PGJ2 is a peroxisome proliferator-activated receptor (PPAR) ligand, and PPARgamma is shown to be expressed by mesangial cells, the thiazolidinedione PPARgamma agonist ciglitazone does not activate ERK. Additionally, a synthetic PPARgamma antagonist does not attenuate the activation of ERK by 15d-PGJ2. 15d-PGJ2-mediated ERK activation is however blocked by the MEK inhibitor PD 098059, appears to require phosphatidylinositol-3 kinase, but is independent of protein kinase C activation. These results demonstrate a novel effect of 15d-PGJ2 to induce ERK in human mesangial cells independently of PPARgamma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11178960     DOI: 10.1006/bbrc.2001.4301

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras.

Authors:  Jose Luis Oliva; Dolores Pérez-Sala; Antonio Castrillo; Natalia Martínez; F Javier Cañada; Lisardo Boscá; José M Rojas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

Review 2.  Formation and signaling actions of electrophilic lipids.

Authors:  Francisco J Schopfer; Chiara Cipollina; Bruce A Freeman
Journal:  Chem Rev       Date:  2011-09-20       Impact factor: 60.622

Review 3.  Milk-derived bioactive peptides and their health promoting effects: a potential role in atherosclerosis.

Authors:  Simone Marcone; Orina Belton; Desmond J Fitzgerald
Journal:  Br J Clin Pharmacol       Date:  2016-06-17       Impact factor: 4.335

4.  15-deoxy-(Delta12,14)-prostaglandin J2 (15d-PGJ2) induces cell death through caspase-independent mechanism in A172 human glioma cells.

Authors:  W H Cho; C H Choi; J Y Park; S K Kang; Y K Kim
Journal:  Neurochem Res       Date:  2006-10       Impact factor: 3.996

5.  Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

Authors:  Salvatore Cuzzocrea; Barbara Pisano; Laura Dugo; Angela Ianaro; Nimesh S A Patel; Rosanna Di Paola; Tiziana Genovese; Prabal K Chatterjee; Massimo Di Rosa; Achille P Caputi; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

Review 6.  Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.

Authors:  Maria E Figueiredo-Pereira; Chuhyon Corwin; John Babich
Journal:  Ann N Y Acad Sci       Date:  2016-01-08       Impact factor: 5.691

Review 7.  PPARγ signaling and emerging opportunities for improved therapeutics.

Authors:  Shuibang Wang; Edward J Dougherty; Robert L Danner
Journal:  Pharmacol Res       Date:  2016-06-04       Impact factor: 7.658

Review 8.  PPAR and immune system--what do we know?

Authors:  Xia Zhang; Howard A Young
Journal:  Int Immunopharmacol       Date:  2002-07       Impact factor: 4.932

9.  15-Deoxy-Delta-Prostaglandin J(2) Upregulates the Expression of LPS-Induced IL-8/CXCL8 mRNA in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats.

Authors:  Jung Hae Kim; Hee Sun Kim
Journal:  Immune Netw       Date:  2009-04-30       Impact factor: 6.303

10.  Abrogation of IL-6-mediated JAK signalling by the cyclopentenone prostaglandin 15d-PGJ(2) in oral squamous carcinoma cells.

Authors:  H Siavash; N G Nikitakis; J J Sauk
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.